Young Ho Seo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3481722/publications.pdf

Version: 2024-02-01

567281 610901 38 651 15 24 citations h-index g-index papers 39 39 39 1042 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Asiatic acid attenuates methamphetamine-induced neuroinflammation and neurotoxicity through blocking of NF-kB/STAT3/ERK and mitochondria-mediated apoptosis pathway. Journal of Neuroinflammation, 2017, 14, 240.	7.2	96
2	Sulforaphane inhibits pancreatic cancer through disrupting Hsp90–p50Cdc37 complex and direct interactions with amino acids residues of Hsp90. Journal of Nutritional Biochemistry, 2012, 23, 1617-1626.	4.2	49
3	A novel class of anthraquinone-based HDAC6 inhibitors. European Journal of Medicinal Chemistry, 2019, 164, 263-272.	5.5	37
4	Organelle-specific Hsp90 inhibitors. Archives of Pharmacal Research, 2015, 38, 1582-1590.	6.3	30
5	Nano-mechanical Reinforcement in Drug-Resistant Ovarian Cancer Cells. Biological and Pharmaceutical Bulletin, 2015, 38, 389-395.	1.4	29
6	Hair Metabolomics in Animal Studies and Clinical Settings. Molecules, 2019, 24, 2195.	3.8	29
7	Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors. European Journal of Medicinal Chemistry, 2018, 143, 390-401.	5.5	24
8	Dual Inhibitors Against Topoisomerases and Histone Deacetylases. Journal of Cancer Prevention, 2015, 20, 85-91.	2.0	23
9	Role of hair pigmentation in drug incorporation into hair. Forensic Science International, 2017, 281, 171-175.	2.2	23
10	Epicatechin Prevents Methamphetamine-Induced Neuronal Cell Death via Inhibition of ER Stress. Biomolecules and Therapeutics, 2019, 27, 145-151.	2.4	23
11	Small Molecule Inhibitors of HSF1-Activated Pathways as Potential Next-Generation Anticancer Therapeutics. Molecules, 2018, 23, 2757.	3.8	22
12	Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC). Bioorganic and Medicinal Chemistry Letters, 2014, 24, 224-227.	2.2	21
13	Small Molecule Inhibitors to Disrupt Protein-protein Interactions of Heat Shock Protein 90 Chaperone Machinery. Journal of Cancer Prevention, 2015, 20, 5-11.	2.0	21
14	YM155 enhances ABT-737-mediated apoptosis through Mcl-1 downregulation in Mcl-1-overexpressed cancer cells. Molecular and Cellular Biochemistry, 2017, 429, 91-102.	3.1	19
15	Design, synthesis and biological evaluation of a series of CNS penetrant HDAC inhibitors structurally derived from amyloid- \hat{l}^2 probes. Scientific Reports, 2019, 9, 13187.	3.3	18
16	Targeting the hydrophobic region of Hsp90's ATP binding pocket with novel 1,3,5-triazines. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6427-6431.	2.2	16
17	A novel chalcone-based molecule, BDP inhibits MDA-MB-231 triple-negative breast cancer cell growth by suppressing Hsp90 function. Oncology Reports, 2017, 38, 2343-2350.	2.6	15
18	Development of a column-switching LC-MS/MS method of tramadol and its metabolites in hair and application to a pharmacogenetic study. Archives of Pharmacal Research, 2018, 41, 554-563.	6.3	15

#	Article	IF	Citations
19	Synthesis and in vitro antiproliferative activity of C5-benzyl substituted 2-amino-pyrrolo[2,3-d] pyrimidines as potent Hsp90 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 237-241.	2.2	14
20	Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide. European Journal of Medicinal Chemistry, 2016, 124, 1069-1080.	5. 5	13
21	Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction. International Journal of Molecular Sciences, 2019, 20, 6213.	4.1	13
22	Chalcone-templated Hsp90 inhibitors and their effects on gefitinib resistance in non-small cell lung cancer (NSCLC). Archives of Pharmacal Research, 2017, 40, 96-105.	6.3	12
23	Aspirin-inspired acetyl-donating HDACs inhibitors. Archives of Pharmacal Research, 2018, 41, 967-976.	6.3	12
24	Design, synthesis, and biological evalution of bifunctional inhibitors against Hsp90-HDAC6 interplay. European Journal of Medicinal Chemistry, 2022, 240, 114582.	5.5	10
25	Discovery of 2′,4′-dimethoxychalcone as a Hsp90 inhibitor and its effect on iressa-resistant non-small cell lung cancer (NSCLC). Archives of Pharmacal Research, 2015, 38, 1783-1788.	6.3	9
26	Discovery of Licochalcone A as a Natural Product Inhibitor of Hsp90 and Its Effect on Gefitinib Resistance in Non-Small Cell Lung Cancer (NSCLC). Bulletin of the Korean Chemical Society, 2013, 34, 1917-1920.	1.9	9
27	Structural Basis for Design of New Purine-Based Inhibitors Targeting the Hydrophobic Binding Pocket of Hsp90. International Journal of Molecular Sciences, 2020, 21, 9377.	4.1	7
28	Synthesis of Flavokawain B and its Anti-proliferative Activity Against Gefitinib-resistant Non-small Cell Lung Cancer (NSCLC). Bulletin of the Korean Chemical Society, 2013, 34, 3782-3786.	1.9	7
29	Synthesis of Flavokawain Analogues and their Anti-neoplastic Effects on Drug-resistant Cancer Cells Through Hsp90 Inhibition. Bulletin of the Korean Chemical Society, 2014, 35, 1154-1158.	1.9	7
30	MeBib Suppressed Methamphetamine Self-Administration Response via Inhibition of BDNF/ERK/CREB Signal Pathway in the Hippocampus. Biomolecules and Therapeutics, 2020, 28, 519-526.	2.4	7
31	Hybrid inhibitors of DNA and HDACs remarkably enhance cytotoxicity in leukaemia cells. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1069-1079.	5.2	5
32	The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs. Oncology Reports, 2018, 39, 1775-1782.	2.6	4
33	Design, synthesis, and biological evaluation of histone deacetylase inhibitor with novel salicylamide zinc binding group. Medicine (United States), 2022, 101, e29049.	1.0	3
34	Repositioning Irsogladine to <scp>Hsp90</scp> Inhibitor. Bulletin of the Korean Chemical Society, 2015, 36, 1495-1499.	1.9	2
35	<i>In Vitro</i> Antifungal Activity and Mode of Action of 2′,4′-Dihydroxychalcone against Aspergillus fumigatus. Mycobiology, 2015, 43, 150-156.	1.7	2
36	Selective targeting of cancer cells using a hydrogen peroxide-activated Hsp90 inhibitor. Bioorganic Chemistry, 2021, 115, 105195.	4.1	2

3

#	Article	lF	CITATIONS
37	Rational Design and Synthesis of HSF1-PROTACs for Anticancer Drug Development. Molecules, 2022, 27, 1655.	3.8	2
38	Evaluation of the Inhibitory Effects of (E)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one (DiNap), a Natural Product Analog, on the Replication of Type 2 PRRSV In Vitro and In Vivo. Molecules, 2019, 24, 887.	3.8	1